Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

April 30, 2012

Conditions
Kidney NeoplasmsCarcinoma, Renal CellKidney (Renal Cell) Cancer
Interventions
PROCEDURE

FDG PET CT

nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body

PROCEDURE

DCE MRI

DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).

DRUG

F-18 Fluoro-deoxi-glucose

15 mCi iv

DRUG

Gadolinium-DTPA

0.1 mmol/kg iv

DRUG

Sunitinib

50 mg/day po

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Stanford University

OTHER

NCT00537056 - Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI | Biotech Hunter | Biotech Hunter